Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cedazuridine/decitabine - Astex Pharmaceuticals

Drug Profile

Cedazuridine/decitabine - Astex Pharmaceuticals

Alternative Names: ASTX-727; ASTX-727-LD; ASTX727-10; Cedazuridine/Decitabine; Decitabine/cedazuridine; Decitabine/E7727; E-7727/decitabine; Inaqovi; INQOVI; Oral C-DEC

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Pharmaceuticals; National Cancer Institute (USA)
  • Developer Astex Pharmaceuticals; Otsuka Pharmaceutical; Taiho Oncology; Taiho Pharma Canada
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Fluorinated hydrocarbons; Pyrimidine nucleosides; Ribonucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; Cytidine deaminase inhibitors; DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Registered Acute myeloid leukaemia
  • Phase I/II Myeloproliferative disorders
  • Phase I Breast cancer; Glioma
  • No development reported Solid tumours

Most Recent Events

  • 14 Mar 2024 Pfizer completes a phase-I clinical trial in Breast cancer (Metastatic disease, Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) (NCT04134884)
  • 07 Mar 2024 M.D. Anderson Cancer Center and Astex Pharmaceuticals initiate a phase Ia/Ib trial in Acute myeloid leukemia (In children, In adolescents, Combination therapy) in USA (PO) (NCT06191978)
  • 31 Dec 2023 Phase-I/II clinical trials in Myelodysplastic syndromes in China (PO), prior to December 2023 (Otsuka Pharmaceutical pipeline, February 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top